{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:18:17Z","timestamp":1788419897245,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Biological therapy is effective for the treatment of psoriasis and psoriatic arthritis; however, adverse effects related to immunosuppression, such as viral infections, have been reported. Amongst these infections, herpes zoster (HZ) is common.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To evaluate the risk of HZ in psoriasis and psoriatic arthritis patients treated with biological therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Data sources:<\/jats:title>\n            <jats:p>A comprehensive literature search of PubMed, Embase, and Web of Science was performed using certain keywords until October 9, 2020. Nine studies were included after a detailed assessment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study eligibility criteria:<\/jats:title>\n            <jats:p>The eligibility criteria included randomized controlled trials (RCTs) and observational studies of patients with psoriasis or psoriatic arthritis treated with biological therapies; compared with non-biological therapies, non-biological systemic therapies, or controls; with the incidence of HZ reported in case and control groups. The Cochrane risk of bias tool and Newcastle-Ottawa scale were used to assess the quality of the RCTs and observational studies, respectively. Data were extracted from 9 eligible studies and then analyzed using Stata software (Version 12.0).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The risk of HZ in biological therapies was higher than that in non-biological (odds ratios [OR]: 1.48; 95% confidence interval [CI]: 1.18\u20131.86; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%) and non-biological systemic (OR: 1.32; 95% CI: 1.02\u20131.71; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%) therapies. Furthermore, the risk of HZ associated with tumor necrosis factor-\u03b1 inhibitors increased significantly (OR: 1.50; 95% CI: 1.11\u20132.02; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%). Notably, infliximab (OR: 2.43; 95% CI: 1.31\u20134.50; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%) and etanercept (OR: 1.65; 95% CI: 1.07\u20132.56; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%) increased the risk of HZ, while adalimumab (OR: 1.21; 95% CI: 0.64\u20132.30; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%), ustekinumab (OR: 2.20; 95% CI: 0.89\u20135.44; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%), alefacept (OR: 1.46; 95% CI: 0.20\u201310.47; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%), and efalizumab (OR: 1.58; 95% CI: 0.22\u201311.34; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%) did not.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Limitations:<\/jats:title>\n            <jats:p>Few RCTs have reported HZ incidents; thus, our results require confirmation via large-scale RCTs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions and implications of key findings:<\/jats:title>\n            <jats:p>Biological therapies, especially tumor necrosis factor-\u03b1 inhibitors, may lead to the risk of HZ in psoriasis and psoriatic arthritis patients. Amongst these agents, infliximab and etanercept have been shown to significantly increase the risk of HZ. Additionally, younger age and female sex may be risk factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Systematic review registration number:<\/jats:title>\n            <jats:p>INPLASY202110027.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027368","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T13:24:54Z","timestamp":1633699494000},"page":"e27368","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis"],"prefix":"10.1097","volume":"100","author":[{"given":"Ailing","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Dermatology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Health Care Group, Huangshi, Hubei, China"},{"name":"Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Health Care Group, Huangshi, Hubei, China"},{"name":"Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Health Care Group, Huangshi, Hubei, China"},{"name":"Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Radiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Health Care Group, Huangshi, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"R1-20250504","first-page":"231","article-title":"Plaque psoriasis \u2013 more than a skin disorder","volume":"40","author":"Staubach","year":"2017","journal-title":"Med Monatsschr Pharm"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3390\/ijms18112297","article-title":"Old and new biological therapies for psoriasis","volume":"18","author":"Ronholt","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11926-019-0832-y","article-title":"In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis","volume":"21","author":"Siegel","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"83.e84","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","article-title":"Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics","volume":"3","author":"Ritchlin","year":"2019","journal-title":"BMC Rheumatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/09546634.2018.1445193","article-title":"Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Shalom","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e0179447","DOI":"10.1371\/journal.pone.0179447","article-title":"Increased risk of herpes zoster in patients with psoriasis: a population-based retrospective cohort study","volume":"12","author":"Tsai","year":"2017","journal-title":"PLoS One"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","article-title":"Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom","volume":"138","author":"Takeshita","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R13-20250504","first-page":"ciaa1192","article-title":"Herpes zoster and postherpetic neuralgia","volume":"2020","author":"Cohen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1468-3083.2011.04230.x","article-title":"Risk of Herpes zoster in patients with psoriasis treated with biologic drugs","volume":"26","author":"Dreiher","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jamadermatol.2017.4840","article-title":"Herpes zoster rates in a large cohort of patients with systemically treated psoriasis","volume":"154","author":"Levandoski","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4103\/0378-6323.183630","article-title":"The risk of herpes zoster in patients with psoriasis: a retrospective records-based observational study","volume":"82","author":"Megna","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2013-205148","article-title":"Psoriatic arthritis treatment and the risk of herpes zoster","volume":"75","author":"Zisman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA Statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R25-20250504","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20250504","first-page":"145","article-title":"Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges","volume":"6","author":"El Hayderi","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.12307","article-title":"The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions","volume":"28","author":"Adelzadeh","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R29-20250504","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R30-20250504","first-page":"189","article-title":"Varicella-zoster virus T cell tropism and the pathogenesis of skin infection","volume":"342","author":"Arvin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"(3 pt 1)","key":"R31-20250504","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/jid.2011.383","article-title":"Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry","volume":"132","author":"Serac","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jdv.13957","article-title":"European consensus-based (S2k) guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: treatment","volume":"31","author":"Werner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:32:15Z","timestamp":1746340335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027368"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":31,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027368","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"2021-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}